Recent Articles from Business Wire

Orion Digital Corp. Announces Monetization of Remaining WonderFi Investment, Strengthening Balance Sheet
Orion Digital Corp. (NASDAQ: ORIO; TSX: ORIO) (“Orion Digital” or the “Company”), a founder-led digital finance platform operating primarily across wealth, payments, and digital assets, today announced that it exited its remaining equity position in WonderFi Technologies Inc. (“WonderFi”), increasing the Company’s cash and cash equivalents by more than 50% over Q3 2025 to approximately CDN$27 million.
By Orion Digital Corp. · Via Business Wire · January 9, 2026
flyExclusive Announces Pricing of $15 Million Public Offering of Common Stock
flyExclusive, Inc. (NYSE American: FLYX) (the “Company” or “flyExclusive”), one of the nation’s leading private aviation operators, today announced the pricing of its previously announced underwritten public offering of 2,255,639 shares of its common stock at a public offering price of $6.65 per share of common stock, before deducting underwriting discounts and commissions and offering expenses.
By flyExclusive, Inc. · Via Business Wire · January 9, 2026
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary financial results and business updates for the fourth quarter and year-ended December 31, 2025.
By Delcath Systems, Inc. · Via Business Wire · January 9, 2026
MEDIPOST Inc. Announces $140 Million in Funding to Accelerate Late-Stage Clinical Development
MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative diseases, today announced that its parent company, MEDIPOST Co., Ltd., has closed on $140 million in funding.
By MEDIPOST Inc. · Via Business Wire · January 9, 2026
Real Chemistry Establishes RC Resolve, an Advisory Practice for Healthcare’s Most Critical Business, Regulatory and Value Inflection Points
Real Chemistry today announced the launch of RC Resolve, a healthcare advisory practice designed to help leaders navigate the value inflection points where science, business, economics, policy and risk management intersect. RC Resolve offers a new end-to-end model of healthcare advisory informed by deep expertise and real-time insights to deliver communication strategies and execution that drive desired outcomes.
By Real Chemistry · Via Business Wire · January 9, 2026
Mammoth Biosciences to Present at 44th Annual J.P. Morgan Healthcare Conference
Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation in vivo CRISPR gene editing platform to create potential one-time curative therapies, today announced its participation in the upcoming 44th Annual J.P. Morgan Healthcare Conference.
By Mammoth Biosciences, Inc. · Via Business Wire · January 9, 2026
Gold Reserve Provides Update in Citgo Sale Process: Gold Reserve Files Appeal
Gold Reserve Ltd. (TSX.V: GRZ) (BSX: GRZ.BH) (OTCQX: GDRZF) (“Gold Reserve” or the “Company”) announces that yesterday the Company filed its opening appeal brief with the U.S. Court of Appeals for the Third Circuit (the “Third Circuit”) in connection with the proposed judicial sale of PDVH Shares to Elliott/Amber Energy.
By Gold Reserve Ltd. · Via Business Wire · January 9, 2026
Bragg Gaming Further Extends PAM Agreement with Entain
Bragg Gaming Group (NASDAQ: BRAG, TSX: BRAG) (“Bragg” or the “Company”), a global iGaming content and technology supplier, is pleased to announce the extension of its existing Player Account Management (“PAM”) agreement with Entain Plc (LSE: ENTL), one of the world’s largest sports betting and gaming groups, for BetCity.nl, a leading Dutch market operator.
By Bragg Gaming Group Inc. · Via Business Wire · January 9, 2026
Bain Capital and BlueWater Marinas Acquire Kent Narrows Boatel
BlueWater Marinas (“BlueWater”) today announced the acquisition of Kent Narrows Boatel (“KNB”), a Class-A, heated drystack marina located just outside of Annapolis in Kent Narrows, MD. KNB will be the fourth marina added to the Bain Capital/BlueWater portfolio.
By Bain Capital Real Estate · Via Business Wire · January 9, 2026
Orca Bio Announces $250M in Aggregate Financing in Preparation for Potential Commercialization
Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced the completion of a Series F financing round in December 2025 led by Lightspeed Venture Partners. With $250M in new equity capital from its two most recent financing rounds, along with a 2025 amendment to its Silicon Valley Bank credit facility providing up to $100M in additional liquidity, Orca Bio possesses the financial strength to scale its commercial operations and advance its clinical pipeline.
By Orca Bio · Via Business Wire · January 9, 2026
Naveris® to Highlight New Publications at the 44th Annual J.P. Morgan Healthcare Conference
Naveris, Inc., the leader in precision oncology diagnostics for viral-driven cancers, today announced that it will be highlighting new data supporting the use of blood-based ctDNA tests to improve post-treatment surveillance protocols in both head-and-neck and anal cancers at the 44th Annual J.P. Morgan Healthcare Conference, to be held January 12-15, 2026, in San Francisco, CA.
By Naveris, Inc. · Via Business Wire · January 9, 2026
Lone Star Acquires Coral Gables Office Complex
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Real Estate Fund VII, L.P., along with an affiliate of Highline Real Estate Capital LLC and Square2 Capital LLC, has successfully completed the acquisition of The Alhambra, an office complex in South Florida.
By Lone Star Funds · Via Business Wire · January 9, 2026
American Pacific Group Announces the Hire of Wyatt Brothers as a Principal
American Pacific Group (“APG”), a San Francisco Bay Area-based private equity firm, announced today that Wyatt Brothers has been hired as a Principal at the firm. He is focused on sourcing, executing, and supporting investments across the firm.
By American Pacific Group · Via Business Wire · January 9, 2026
Gold Reserve Announces Stock Option Grants
Gold Reserve Ltd. (TSX.V: GRZ) (BSX: GRZ.BH) (OTCQX: GDRZF) (“Gold Reserve” or the “Company”) announces that it has granted a total of 1,525,000 stock options (the “Options”) to directors, officers, employees and certain key consultants of the Company. The Options are exercisable for a period of five years at an exercise price of US$3.64 per share. The Options were issued pursuant to the Company’s 2012 Equity Incentive Plan, as amended, and in accordance with the requirements of the TSX Venture Exchange and the Bermuda Stock Exchange.
By Gold Reserve Ltd. · Via Business Wire · January 9, 2026
Vivasure Medical Announces Acquisition by Haemonetics Corporation
Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced that the company has been acquired by Haemonetics Corporation (NYSE: HAE) in a transaction valued up to €185M (~$215M) on completion of certain milestones.
By Vivasure Medical · Via Business Wire · January 9, 2026
RADAR Names Former PVH/Lululemon Executive Jonathan Aitken to Lead RFID Center of Excellence
RADAR, the technology platform that leverages RFID overhead sensor technology to track and precisely locate in-store inventory with 99% accuracy across Old Navy, American Eagle and other top retailers, today announced three leadership appointments and several internal promotions to support growing customer demand and global expansion.
By RADAR · Via Business Wire · January 9, 2026
Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models
Revvity, Inc. (NYSE: RVTY) today announced a collaboration with Eli Lilly and Company (Lilly) that expands access to Lilly’s high-quality predictive models by making Lilly TuneLab available through the Revvity Signals platform. The collaboration builds on Revvity’s recently introduced Signals XyntheticaTM offering, creating a scalable, federated framework designed to accelerate AI-enabled drug discovery.
By Revvity · Via Business Wire · January 9, 2026
AirNexis Therapeutics Launches with $200M Series A to Advance Phase 2 Dual PDE3/4 Inhibitor AN01 for Chronic Obstructive Pulmonary Disease (COPD)
AirNexis Therapeutics, a clinical stage biotech company developing therapeutics for pulmonary diseases, today announced the close of a $200 million Series A financing round and the in-license of a dual PDE3/4 inhibitor in Phase 2 development for chronic obstructive pulmonary disease (COPD) from Haisco Pharmaceutical Group. The over-subscribed Series A was led by Frazier Life Sciences, with participation from OrbiMed, SR One, Life Sciences at Goldman Sachs Alternatives, Longitude Capital and Enavate Sciences among others. Proceeds of the financing will fund the global clinical development of AN01.
By AirNexis Therapeutics · Via Business Wire · January 9, 2026
Ouster Announces Participation in the 28th Annual Needham Growth Conference
Ouster, Inc. (Nasdaq: OUST) (“Ouster” or the “Company”), a global leader in high-performance lidar sensors and intelligent software solutions that bring Physical AI to life across the automotive, industrial, robotics, and smart infrastructure sectors, today announced that Ouster management will participate in the upcoming investor event:
By Ouster, Inc. · Via Business Wire · January 9, 2026
Franklin Street Properties Corp. Declares Quarterly Dividend
Franklin Street Properties Corp. (“FSP”, “our” or “we”) (NYSE American: FSP) announced today that its Board of Directors declared a quarterly dividend of $0.01 per share of common stock for the period October 1, 2025 through December 31, 2025, payable on February 12, 2026 to stockholders of record as of January 23, 2026.
By Franklin Street Properties Corp. · Via Business Wire · January 9, 2026
Viper Partners Announces Major National Initiative to Fuel Dental Sector Resurgence in 2026
Viper Partners, the premier investment banking and M&A advisory firm specializing in dentistry since its founding in 2009, today announced a significant nationwide capital commitment aimed at accelerating mergers, acquisitions, and recapitalizations across the dental industry. With an unmatched track record of guiding hundreds of successful transactions, Viper is positioning 2026 as the pivotal year for dental practice owners to achieve optimal exits and for private equity firms to drive renewed growth.
By Viper Partners · Via Business Wire · January 9, 2026
Marqeta to Announce Fourth Quarter and Full Year 2025 Results on February 24, 2026
Marqeta, Inc. (NASDAQ: MQ), the global modern card issuing platform, today announced that it will host a conference call and webcast to discuss fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026 at 4:30 pm ET. Hosting the call will be Mike Milotich, Chief Executive Officer and Patti Kangwankij, Chief Financial Officer. A press release with the fourth quarter and full year 2025 financial results will be issued after the market closes that same day.
By Marqeta · Via Business Wire · January 9, 2026
Aircraft Machining Industry Research Report 2025: Segment Analysis, Regional Aircraft Projections, Defense Spending Trends, and Commercial & Business Jet Delivery Roadmaps 2019-2032 - ResearchAndMarkets.com
The "Aircraft Machining Market Size, Share, Trend, Forecast, Competitive Analysis, and Growth Opportunity: 2025-2032" report has been added to ResearchAndMarkets.com's offering.
By Research and Markets · Via Business Wire · January 9, 2026
McGraw Hill to Release Fiscal Third Quarter 2026 Financial Results and Host Webcast on February 11, 2026
McGraw Hill, Inc. (NYSE: MH), a leading global provider for education solutions from preK-12 through higher education and professional learning, will report fiscal third quarter financial results for the period ended December 31, 2025, on Wednesday, February 11, 2026.
By McGraw Hill · Via Business Wire · January 9, 2026
Elucid Announces Broad Reimbursement for Quantitative Coronary Plaque Analysis
Elucid today announced that, effective January 1, 2026, its Plaque-IQ™ coronary plaque analysis has received a new Category I Current Procedural Terminology (CPT®) designation, alongside increasingly widespread coverage and reimbursement from both public and private payors. Together, these developments underscore the clinical value of coronary plaque analysis and establish favorable conditions for broader adoption of the technology.
By Elucid · Via Business Wire · January 9, 2026
Aircraft Avionics MRO Research Report 2025: $10.3 Bn Market Share, Trends, Dynamics, Forecast, & Growth Analysis 2024-2035 - ResearchAndMarkets.com
The "Aircraft Avionics MRO Market Size, Share, Trends, Dynamics, Forecast, & Growth Analysis: 2025-2035" report has been added to ResearchAndMarkets.com's offering.
By Research and Markets · Via Business Wire · January 9, 2026
Polestar reports record retail sales in 2025
Polestar (Nasdaq: PSNY) retail sales amounted to an estimated 15,608 cars in Q4 2025, up 27% versus Q4 2024. For the full year, retail sales totalled approximately 60,119 cars, a growth of 34% compared to 2024.
By Polestar · Via Business Wire · January 9, 2026
Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026.
By Pulse Biosciences, Inc. · Via Business Wire · January 9, 2026
Molson Coors Beverage Company Announces 2025 Fourth Quarter and Full Year Earnings Date and Participation at the 2026 Consumer Analyst Group of New York (CAGNY) Conference
Molson Coors Beverage Company (NYSE: TAP, TAP.A; TSX: TPX.B, TPX.A) will release its 2025 Fourth Quarter and Full Year earnings results on Wednesday, February 18, 2026 at approximately 4 p.m. Eastern Time.
By Molson Coors · Via Business Wire · January 9, 2026
Upbound Group, Inc. to Participate in the 2026 ICR Conference
Upbound Group, Inc. (“Upbound” or the “Company”) (NASDAQ: UPBD), a technology and data-driven leader in accessible and inclusive financial solutions that address the evolving needs and aspirations of underserved consumers, today announced that Fahmi Karam, CEO, and Hal Khouri, CFO, will participate in a Fireside Chat presentation at the 2026 ICR Conference in Orlando, Florida, on Tuesday, January 13, at 3:30 PM ET. A live webcast of the presentation will be available at https://investor.upbound.com.
By Upbound Group, Inc. · Via Business Wire · January 9, 2026
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs).
By Biocytogen · Via Business Wire · January 9, 2026
Bruker Announces $500 Million in Multi-Year Orders from Two Global Healthcare Companies for Supply of High-Performance Superconductors for MRI
The Bruker Energy & Supercon Technologies (BEST) division, a segment of Bruker Corporation (Nasdaq: BRKR), today announced two multi-year supply agreements for Bruker’s latest superconductors, which are used by global radiology companies to build their next generations of magnetic resonance imaging (MRI) magnets.
By Bruker Corporation · Via Business Wire · January 9, 2026
Clarametyx Biosciences Announces Positive Topline Data From Phase 2a Study Evaluating CMTX-101 in Cystic Fibrosis
Clarametyx Biosciences, Inc. (“Clarametyx”), a clinical-stage biotechnology company developing immune-enabling therapies and vaccines to address biofilm-driven chronic respiratory diseases, today announced positive topline data from a Phase 1b/2a clinical trial evaluating its novel immune-enabling antibody therapy, CMTX-101, in the treatment of people with cystic fibrosis (pwCF). These findings support further development of CMTX-101 in a Phase 2 bronchiectasis trial.
By Clarametyx Biosciences, Inc. · Via Business Wire · January 9, 2026
Nu Skin Enterprises to Discuss Company Strategy and Opportunities at ICR Conference
Nu Skin Enterprises Inc. (NYSE: NUS) today announced president and CEO Ryan Napierski will participate in a moderated fireside chat to discuss company strategy and the state of the business on Monday, Jan. 12. The discussion will include the company’s plans in 2026 for launching its Prysm iO intelligent wellness device and future opportunities in emerging markets, including India.
By Nu Skin Enterprises Inc. · Via Business Wire · January 9, 2026
Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign
Schrödinger, Inc. (Nasdaq: SDGR) today announced a collaboration with Lilly TuneLab™, a platform launched by Eli Lilly and Company (Lilly) designed to accelerate drug discovery and development by providing access to advanced artificial intelligence (AI) capabilities. TuneLab will be made available in LiveDesign, Schrödinger’s widely used enterprise informatics platform, as a priority interface for participating biotech companies to access TuneLab workflows.
By Schrödinger · Via Business Wire · January 9, 2026
GC Therapeutics Appoints Kate Haviland as Board Chair and Provides Corporate Update
GC Therapeutics, Inc. (GCTx), a biotechnology company created to scale and unlock the next generation of cell therapy-based medicines through its TFome™ cellular programming platform, today announced a series of corporate and pipeline updates.
By GC Therapeutics, Inc. · Via Business Wire · January 9, 2026
Bullish releases December 2025 monthly metrics
Bullish (NYSE: BLSH), an institutionally focused global digital asset platform that provides market infrastructure and information services, released its monthly metrics for December 2025 on Friday, January 9, 2026.
By Bullish · Via Business Wire · January 9, 2026
Lindsay Corporation Announces Quarterly Cash Dividend
Lindsay Corporation (NYSE: LNN), a leading global manufacturer and distributor of irrigation and infrastructure equipment and technology, announced today that its Board of Directors has declared a regular quarterly cash dividend of $0.37 per share, payable February 27, 2026, to shareholders of record at the close of business on February 13, 2026.
By Lindsay Corporation · Via Business Wire · January 9, 2026
Humana Inc. to Release Fourth Quarter 2025 Results on February 11, 2026
Humana Inc. (NYSE: HUM) will release its financial results for the fourth quarter 2025 (4Q25), as well as prepared management remarks (in PDF format), at 6:00 a.m. Eastern time on February 11, 2026. The company will host a live question-and-answer session at 8:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2026.
By Humana Inc. · Via Business Wire · January 9, 2026
Cresco Labs Opens Sunnyside Tamarac, Expanding Patient Access in Broward County, Florida
Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today announced the grand opening of Sunnyside Tamarac, located at 6001 N University Drive in Tamarac, Fla. It is the Company’s 31st dispensary in Florida and 72nd nationwide.
By Cresco Labs · Via Business Wire · January 9, 2026
Carter’s, Inc. Provides Business Update
Carter’s, Inc. (NYSE:CRI), North America’s largest and most-enduring apparel company exclusively for babies and young children, today announced preliminary net sales results for the fourth quarter and fiscal year 2025, participation at an upcoming investor conference, and an addition to the Company’s management team.
By Carter’s, Inc. · Via Business Wire · January 9, 2026
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis
Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Food and Drug Administration (FDA) Division of Hepatology and Nutrition has granted Kezar a Type C meeting for the first quarter to discuss the development of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with autoimmune hepatitis (AIH).
By Kezar Life Sciences, Inc. · Via Business Wire · January 9, 2026
Linde Announces Fourth Quarter 2025 Earnings and Conference Call Schedule
Linde (Nasdaq: LIN) will release its fourth quarter 2025 financial results by 06:00 EST/midday CET on Thursday, February 5, 2026. The Company will host and webcast its conference call at 09:00 EST/15:00 CET, which will be available to the public and the media in listen-only mode.
By Linde · Via Business Wire · January 9, 2026
Oklo, Meta Announce Agreement in Support of 1.2 GW Nuclear Energy Development in Southern Ohio
Oklo Inc. (NYSE: OKLO) (Oklo), an advanced nuclear technology company, announced an agreement with Meta Platforms, Inc. (Nasdaq: META) that advances Oklo’s plans to develop a 1.2 GW power campus in Pike County, Ohio, to support Meta’s data centers in the region. The agreement provides a mechanism for Meta to prepay for power and provide funding to advance project certainty for Oklo’s Aurora powerhouse deployment.
By Oklo Inc. · Via Business Wire · January 9, 2026
Aurora Therapeutics Launches to Realize Potential of Personalized Gene Editing for Millions of Patients with Rare Diseases
Aurora Therapeutics today announced its official launch to transform personalized gene editing from a one-patient breakthrough into a scalable model capable of bringing therapies to millions of patients with rare diseases. The company launches with a $16 million seed financing from Menlo Ventures to create the first platform for treating rare genetic mutations that have historically been impossible to address at scale.
By Aurora Therapeutics · Via Business Wire · January 9, 2026
Pacifico Energy Achieves Commercial Operations at Sunpro Wind Farm in Vietnam’s Mekong Delta
Pacifico Energy Vietnam (“PEV”), the Vietnam-based development platform of Pacifico Energy Group (“PEG”), a leading global energy infrastructure developer, today announced the commencement of commercial operations at its 30 MW Sunpro Wind Farm (“Sunpro”), adding new power capacity to Vietnam’s national grid, supporting the country’s transition to clean energy. Located in Thới Thuận Commune, Vĩnh Long Province in the Mekong Delta, Sunpro achieved commercial operations on December 19, 2025. PEG owns 100% of Sunpro, which is backed by a 20-year feed-in tariff with Vietnam Electricity Group (“EVN”), providing stable, long-term revenue.
By Pacifico Energy Vietnam · Via Business Wire · January 9, 2026
ARDT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Ardent Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Ardent Health, Inc. (NYSE: ARDT) securities between July 18, 2024 and November 12, 2025, inclusive (the “Class Period”), have until March 9, 2026 to seek appointment as lead plaintiff of the Ardent Health class action lawsuit. Captioned Postiwala v. Ardent Health, Inc., No. 26-cv-00022 (M.D. Tenn.), the Ardent Health class action lawsuit charges Ardent Health and certain of Ardent Health’s top executives with violations of the Securities Exchange Act of 1934.
By Robbins Geller Rudman & Dowd LLP · Via Business Wire · January 9, 2026
Insulet to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the fourth quarter and full year of 2025 on February 18, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time).
By Insulet Corporation · Via Business Wire · January 9, 2026
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets.
By Komainu · Via Business Wire · January 9, 2026
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy.
By Allianz SE · Via Business Wire · January 9, 2026
TP ICAP to Acquire Vantage Capital Markets, Expanding Global Broking Capabilities
TP ICAP Group, a world-leading provider of market infrastructure, has agreed to acquire Vantage Capital Markets (Vantage), a global brokerage with significant presence in London, Hong Kong, Tokyo, and Dubai.
By TP ICAP Group · Via Business Wire · January 9, 2026
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD).
By MRM Health NV · Via Business Wire · January 9, 2026
Survey Finds Over 70% of Chinese Doctors Recommend “AI Doctor Services” Like Ant Group’s AQ for Everyday Health Needs
A recent survey by Life Times, a well-known Chinese public health media outlet, shows that AI doctor services are broadly supported by doctors in China. Among 500 physicians from the country’s top-tier (tertiary) hospitals, more than 70% said they would recommend AI doctor services to patients for everyday health questions and routine health management.
By Ant Group · Via Business Wire · January 8, 2026
OPPO Joins VVC Advance Patent Pool as a Licensee and Extends HEVC Advance License
Access Advance LLC and Guangdong OPPO Mobile Telecommunications Corp., Ltd. (OPPO) today announced that OPPO has joined the VVC Advance Patent Pool as a Licensee and renewed its HEVC Advance License.
By Access Advance LLC · Via Business Wire · January 8, 2026
Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments
Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The joint agreement meets the requests laid out by President Trump to the industry and provides the Company’s pharmaceutical products an exemption from tariffs1.
By Johnson & Johnson · Via Business Wire · January 8, 2026
TrueBlue Highlights Recent Board Refreshment and Strategic Initiatives Underway to Achieve Long-Term Profitable Growth
TrueBlue, Inc. (NYSE: TBI) (“TrueBlue” or the “Company”) today issued the following statement in response to the comments made by, and nominations from, EHS Management, LLC (“EHS”):
By TrueBlue, Inc. · Via Business Wire · January 8, 2026
Fluor Achieves Mechanical Completion on BASF’s New Verbund Site Project in South China
Fluor Corporation (NYSE: FLR) announced today that it has achieved mechanical completion on BASF’s Zhanjiang Verbund project in China – BASF’s largest investment to date. The achievement was delivered with an outstanding safety record of more than 75 million work hours without a Lost Time Injury.
By Fluor Corporation · Via Business Wire · January 8, 2026
Rosen Law Firm Encourages Nestlé S.A. Investors to Inquire About Securities Class Action Investigation – NSRGY
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Nestlé S.A. (OTC: NSRGY) resulting from allegations that Nestlé may have issued materially misleading business information to the investing public.
By Rosen Law Firm · Via Business Wire · January 8, 2026
Murphy Oil Corporation Announces Pricing of $500 Million of 6.500% Senior Notes Due 2034
Murphy Oil Corporation (the “Company”) (NYSE: MUR) announced today that it has priced an offering of $500 million of 6.500% Senior Notes due 2034 pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission (“SEC”).
By Murphy Oil Corporation · Via Business Wire · January 8, 2026
Veteran Commercial Banker, Colin Murphy, Joins WaFd Bank as Regional President of Northern Oregon
WaFd, Inc. (Nasdaq: WAFD) (the “Company”), the parent company of WaFd Bank, announced that Colin Murphy has joined the organization as Regional President for Northern Oregon. In this role, Murphy will lead the bank’s commercial and retail banking strategy across the region, with a focus on client relationships, team development, and community engagement.
By WaFd, Inc. · Via Business Wire · January 8, 2026
Western Alliance Bank Appoints David Hutzler Head of Private Client Group in Las Vegas
Western Alliance Bank (NYSE:WAL) today announced that it has named David Hutzler head of the Western Alliance Private Client Group in Las Vegas.
By Western Alliance Bank · Via Business Wire · January 8, 2026
TLX Deadline Tomorrow: Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action First Filed by the Firm – TLX
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the “Class Period”) of the important January 9, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.
By The Rosen Law Firm, P.A. · Via Business Wire · January 8, 2026
Apartments.com Releases Multifamily Rent Growth Report for December 2025
Today Apartments.com, an industry-leading online marketplace of CoStar Group (NASDAQ: CSGP), published its latest report on multifamily rent trends for December 2025.
By CoStar Group · Via Business Wire · January 8, 2026
Monnit Enters Japanese Market Through Partnership With Widetec
Monnit, a global leader in Internet of Things (IoT) solutions, today announced a master partnership with Tokyo-based Widetec, a leading IT infrastructure company. Under the agreement, Widetec is authorized to sell and distribute Monnit ALTA® Wireless Sensors and related IoT solutions across Japan.
By Monnit Corporation · Via Business Wire · January 8, 2026
Rosen Law Firm Urges Varonis Systems, Inc. (NASDAQ: VRNS) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Varonis Systems, Inc. (NASDAQ: VRNS) common stock between February 4, 2025 and October 28, 2025, both dates inclusive (the “Class Period”). Varonis is a global security company.
By The Rosen Law Firm, P.A. · Via Business Wire · January 8, 2026
FineHeart Secures €83 Million to Support Its Growth and Establish Itself as a Future European Leader in Active Implantable Medical Devices (AIMDs)
FineHeart, a clinical-stage medical technology company specializing in the development of innovative solutions for cardiology, announced today the completion of a €35 million first closing of its Series C financing round. This funding is a key lever for activating European public funding, IPCEI Tech4Cure1, and for establishing its role as a European Active Implantable Medical Devices (AIMDs) leader.
By FineHeart · Via Business Wire · January 8, 2026
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective January 5th, 2026, to three non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 212,500 shares of the Company’s common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan (“2023 Inducement Plan”). The award was granted as an inducement material to the employees entering into employment with Gossamer in accordance with Nasdaq Listing Rule 5635(c)(4).
By Gossamer Bio, Inc. · Via Business Wire · January 8, 2026
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, on Monday, January 12, 2026, at 5:15 p.m. Pacific Time.
City Ventures Announces Official Grand Opening of Parkside at Cherry Blossom Row in Richmond—the Bay Area’s Best-Kept Secret
City Ventures, California’s leading builder of solar-powered, ecologically responsible homes, has announced the highly anticipated Grand Opening of Parkside at Cherry Blossom Row, an all-electric, solar-powered townhome community located within the East Bay in the Richmond Annex. Pristine, beautifully furnished model homes will open to the public on Saturday, January 10 from 11 am to 2 pm.
By City Ventures · Via Business Wire · January 8, 2026
Heartland Renaissance Fund Secures New Markets Tax Credit Allocation to Fuel Economic Growth
Heartland Renaissance Fund (HRF), an affiliate of ACC Capital, is pleased to announce it has received $85 million in New Markets Tax Credits (NMTC) allocations from the U.S. Department of the Treasury’s Community Development Financial Institutions (CDFI) Fund. The allocation will enable HRF to leverage private investment capital to drive job creation and economic development across communities throughout Arkansas, Louisiana, Missouri, Mississippi, Oklahoma, Tennessee, and Texas.
By ACC Capital · Via Business Wire · January 8, 2026
Guidewire Announces $500.0 Million Share Repurchase Program and Completion of Prior Authorization
Guidewire (NYSE: GWRE), provider of the industry platform Property and Casualty (P&C) insurers rely upon, today announced that it has completed its share repurchase program previously authorized in September 2022 and that, effective immediately, its board of directors has approved a new share repurchase program with authorization to purchase up to $500.0 million of its outstanding shares of common stock.
By Guidewire Software, Inc. · Via Business Wire · January 8, 2026
Amphenol Appoints Sanjiv Lamba to Board of Directors
Amphenol Corporation (NYSE: APH) today announced that Sanjiv Lamba has been appointed to Amphenol’s board of directors. With his appointment, the size of the Company’s board has increased to nine members.
By Amphenol Corporation · Via Business Wire · January 8, 2026
Deluxe to Implement Visa Direct to Enable Fast, Seamless Payments with dlxFastFunds
Deluxe (NYSE: DLX), a trusted Payments and Data company, today announced its collaboration with Visa to implement Visa Direct. This collaboration introduces dlxFastFundsSM, a funding solution that leverages Visa’s trusted payment network to help businesses take control of their cash flow by skipping the typical one- to two-day settlement delay.
By Deluxe Corporation · Via Business Wire · January 8, 2026
RiverNorth Capital and Income Fund, Inc. Announces Final Results of Repurchase Offer
RiverNorth Capital and Income Fund, Inc. (the “Fund”) (NYSE: RSF), a closed-end fund, announced the final results of its repurchase offer for up to 5% of its outstanding common shares. The repurchase offer expired at 5:00 P.M. Eastern Time on January 7, 2026.
KYOCERA NIXKA Inkjet Systems Announces the Worldwide Launch of the Belharra Inkjet Photo Printer
Kyocera Corporation (TOKYO: 6971)(President: Hideo Tanimoto; “Kyocera”) announced today that its group company, KYOCERA NIXKA Inkjet Systems S.A.S. (President: Paul Morgavi; “KNIS”), will simultaneously launch its industrial inkjet photo printer "Belharra" worldwide. After a strong reception in Europe and successful testing in real-world production (Beta installation at Photoweb), KNIS is now bringing it to the global market. The new industrial inkjet photo printer offers a modern, sustainable, and scalable alternative to traditional photo printing, letting print providers worldwide produce high-quality photos more efficiently and with less environmental impact.
By KYOCERA Corporation · Via Business Wire · January 8, 2026